CorMedix is a biopharmaceutical company that develops and commercializes therapeutic products for serious and life-threatening infections and related conditions. The company's core marketed product is DefenCath®, an FDA-approved antimicrobial catheter lock solution that reduces catheter-related bloodstream infections in hemodialysis patients, and it also operates a commercial portfolio of infectious disease treatments including candidates for serious gram-negative and fungal infections, as well as a cardiovascular medication, following its acquisition of complementary infectious disease assets. CorMedix generates revenue through reimbursement from Medicare and government healthcare programs for DefenCath in both inpatient and outpatient dialysis settings, and from hospital and outpatient infusion centers for its broader anti-infective portfolio, while pursuing clinical development programs in additional patient populations and disease indications.